研究概要
我们的发现凸显了利用Nur77激动作用提升基于NK细胞的HCC免疫治疗效果的潜力。
中文摘要
尽管作为新兴的“现货型”抗癌疗法发展前景广阔,自然杀伤(NK)细胞在实体瘤微环境(TME)中仍面临诸多挑战,包括穿透性差和免疫抑制。在此,我们利用空间和单细胞转录组学揭示了Nur77在NK细胞介导的抗肝细胞癌(HCC)免疫中的作用。对人类和小鼠HCC肿瘤的正交分析表明,编码Nur77的NR4A1的表达与NK细胞增殖、免疫刺激性AP-1基因调控子的激活以及HCC中更好的无病生存期相关。在NK细胞中条件性敲除Nr4a1会扰乱其稳态,并在多种肿瘤模型中加速肿瘤进展。相反,在离体或体内对NK细胞中Nur77的激动性激活可增强其抗肿瘤功能。在机制上,下游功能实验证实Nur77激活减弱NK细胞中CD36的表达,并赋予其对TME中oxLDL介导的免疫抑制的抗性。总之,我们的发现凸显了利用Nur77激动作用改善基于NK细胞的HCC免疫治疗的潜力。
展开英文摘要原文
Despite promising development as emerging "off-the-shelf" therapeutics against cancer, natural killer (NK) cells still faced considerable challenges in the solid tumor microenvironment (TME), including poor penetrance and immuno-suppression. Here, we employ spatial and single-cell transcriptomics to reveal a role for Nur77 in NK cell-mediated immunity against hepatocellular carcinoma (HCC). Orthogonal analysis of human and mouse HCC tumors indicate that the expression of NR4A1, encoding Nur77, is associated with NK cell proliferation, activation of the immunostimulatory AP-1 gene regulons, and better disease-free survival in HCC. Conditional ablation of Nr4a1 in NK cells perturbs their homeostasis and accelerates tumor progression in multiple tumor models. Conversely, the agonistic activation of Nur77 in NK cells ex-vivo or in-vivo enhances their anti-tumor functions. Mechanistically, downstream functional assays confirm that Nur77 activation attenuates CD36 expression in NK cells and confers resistance against oxLDL-mediated immunosuppression in the TME. Collectively, our findings highlight the potential of harnessing Nur77 agonism in improving NK cell-based immunotherapy against HCC.
论文信息
- 作者
- Neo SY、Mei Y、Chong J、Lee KY、Lim JY、Rajapakse MP、Shuen TWH、Zhao J
- 第一作者单位
- Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore. neo_shi_yong@a-star.edu.sg.Singapore
- 通讯作者单位
- Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore. lam_kong_peng@a-star.edu.sg.Singapore
- 期刊
- Nature communications2026 Jun 30